Blood tests showed elevated alkaline phosphatase of 226 U/L and alanine transaminase
of 126 U/L.
Repeat complete blood count showed that lymphocytes and thrombocytes had returned to normal, along with serum creatinine and alanine transaminase
0 Erythrocyte sedimentation rate (N = <10 mm/h) 25 Creatine kinase [peak] (N = <200 UI/L) 5,874  Lactate dehydrogenase (N = 100-620 UI/L) 1,968 Aspartate transaminase (N = <50 UI/L) 22 Alanine transaminase
(N = <60 UI/L) 90 Triglycerides (N = 0.
In SOLITAIRE-IV Cempra reported that grade 3 increase in levels of alanine transaminase
(ALT) occurred in 8% of patients on solithromycin and in 3% of patients on moxifloxacin.
35 Aspartate transaminase (units/L) 28 0-35 Alanine transaminase
(units/L) 17 0-35 Alkaline phosphatase (units/L) 132 36-92 Erythrocyte sedimentation rate (mm/h) 61 0-22
3]/[micro]L 150-350 Aspartate transaminase, IU/L 13-33 Alanine transaminase
, IU/L 8-42 Lactate dehydrogenase, IU/L 119-229 C-reactive protein, mg/L 0-0.
Key laboratory abnormalities (incidence of at least 25%) were decreased hemoglobin (84%), increased alanine transaminase
(80%), increased aspartate transaminase (75%), increased creatinine (58%), increased glucose (49%), decreased phosphate (36%), and increased lipase (28%).
He began showing signs of multisystem organ failure with respiratory failure requiring mechanical ventilation, transaminitis with alanine transaminase
(ALT) >1400 and aspartate aminotransferase (AST) >2800 and renal failure requiring continuous renal replacement therapy.
2 mg/dl, serum aspartate transaminase 114 U/l, serum alanine transaminase
39 U/l and serum alkaline transferase 221 U/l.
Patients with alanine transaminase
(ALT) or aspartate transaminase (AST) [greater than or equal to] 40 U/L were excluded to avoid including higher degree of liver injury, non-alcoholic "steatohepatitis" (NASH) and other causes of hepatitides.
Blood tests were all within normal range with the exception of a mild elevation in alanine transaminase
(ALT) and aspartate transaminase (AST).
The following battery of 21 tests was performed on a Hitachi 747 Analyzer (Boehringer Mannheim, Mannheim, Germany), which required 250 [micro]L of plasma: alkaline phosphatase, alanine transaminase
, aspartate transaminase, creatine phosphokinase, lactate dehydrogenase, total bilirubin, albumin, total protein, globulin, cholesterol, glucose, calcium, phosphorus, total carbon dioxide, sodium, potassium, chloride, urea nitrogen, creatinine, gamma glutamic transaminase, and uric acid.
With hepatic and pancreatic function partially stabilised (aspartate aminotransferase 43 U/l, alanine transaminase
129 U/l, creatine phospokinase 413 U/l, lipase 584 U/l, International Normalized Ratio 0.
Linear regression models were fitted for In-transformed values of alanine transaminase
(ALT), [gamma]-glutamyltransferase, and direct bilirubin on PFOA, PFOS, and potential confounders, and logistic regression models were used to compare deciles of PFOA or PFOS in relation to high biomarker levels.
05) increase in the serum concentrations of aspartate transaminase (AST), alanine transaminase
(ALT), and alkaline phosphatase (ALP) of animals treated with the extract of E.